PCSK9, which reduces LDL receptor recycling, is increased. E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function, but its role in familial hypercholesterolemia (FH ...

对此，近年来备受瞩目的PCSK9单抗类药物与他汀类药物的联合治疗方案应用越来越广泛，但在给药频率上仍存在一定局限性，患者需要每日服用他汀 ...

1月10日，恒瑞医药的一款抗PCSK9药物瑞卡西单抗获国家药监局批准上市，成为最新一款获批上市的国产靶向PCSK9的降脂药物。此前，已有6款PSCK9药物 ...

近年来，一种新型降脂药物——PCSK9抑制剂进入临床应用，药物通过皮下注射的方式给药，具有长效性和便捷性的优势，可以每2周到每6个月注射一次 ...

PCSK9抑制剂的使用正在为临床上难治性高胆固醇血症以及他汀类药物不耐受的患者群体开辟全新的治疗前景。 1月10日，恒瑞医药的一款抗PCSK9药物瑞 ...

single-course solution for tackling high cholesterol levels. “Statins and PCSK9 inhibitors are phenomenal meds and we have so much evidence that they can reduce risk, but we see a huge gap in ...

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

对此，近年来备受瞩目的PCSK9单抗类药物与他汀类药物的联合治疗方案应用越来越广泛，但在给药频率上仍存在一定局限性，患者需要每日服用他汀 ...

High cholesterol levels lead to plaque formation in arteries that restrict blood and oxygen flow. Familial ...